Related Experiment Videos
Thrombolytic treatment and proteinuria
M Lynch1, N V Hoffmann, C N Aroney
1Department of Medicine, University of Queensland, Brisbane, Australia.
British Heart Journal
|October 1, 1995
Summary
Streptokinase treatment for acute myocardial infarction caused temporary, glomerular proteinuria in most patients. Renal function remained stable, suggesting immune complex deposition as the cause.
Area of Science:
- Nephrology
- Cardiology
- Immunology
Background:
- Acute myocardial infarction (AMI) treatment often involves thrombolytic therapy.
- Streptokinase is a commonly used thrombolytic agent.
- Potential effects of thrombolysis on renal function require investigation.
Purpose of the Study:
- To assess renal function changes in AMI patients receiving streptokinase.
- To investigate the incidence and characteristics of proteinuria post-streptokinase administration.
Main Methods:
- Prospective study of 60 AMI patients.
- Assessment of proteinuria, creatinine clearance, serum urea, and creatinine.
- Measurement of streptokinase IgG antibody titres.
Main Results:
- 82% of patients receiving streptokinase developed significant proteinuria of glomerular origin.
- Proteinuria resolved by day 3 in the streptokinase group.
- No significant differences in creatinine clearance or serum urea/creatinine levels were observed between groups.
- Elevated streptokinase IgG titres correlated with proteinuria onset and subsequent changes.
Conclusions:
- Streptokinase is associated with early-onset, transient glomerular proteinuria.
- This proteinuria does not lead to a decline in overall renal function.
- Immune complex deposition is a likely mechanism, indicated by the temporal relationship with antibody titres.